Abstract
Efficient and minimally invasive drug delivery systems have been developed to treat intractable human diseases. One approach has been the development of chimeric vector systems combining at least two different vector systems. Based on this concept, chimeric drug delivery systems that combine viral and non-viral features have been developed. Fusigenic non-viral particles have been constructed by conferring viral fusion proteins onto non-viral vectors. HVJ (hemagglutinating virus of Japan; Sendai virus)-liposomes were constructed by the combination of DNA-loaded liposomes with a fusigenic envelope derived from HVJ (hemagglutinating virus of Japan, Sendai virus). Reconstituted HVJ-liposomes were also developed by the insertion of isolated fusion proteins of HVJ into DNA-loaded liposomes. Recently, the technology has been developed to incorporate macromolecules directly into inactivated HVJ particles without liposomes. The resulting HVJ envelope vector introduced plasmid DNA, efficiently and rapidly into both cultured cells in vitro and organs in vivo . Furthermore, proteins, synthetic oligonucleotides and drugs have also been effectively introduced into cells using the HVJ envelope vector. The HVJ envelope vector will be a promising tool for both ex vivo and in vivo gene therapy experiments.
Keywords: chimeric vector, non-viral vector, hvj, cell fusion, hvj-liposomes, hvj envelope vector, gene therapy
Current Drug Targets
Title: New Vector Innovation for Drug Delivery: Development of Fusigenic Non- Viral Particles
Volume: 4 Issue: 8
Author(s): Yasufumi Kaneda
Affiliation:
Keywords: chimeric vector, non-viral vector, hvj, cell fusion, hvj-liposomes, hvj envelope vector, gene therapy
Abstract: Efficient and minimally invasive drug delivery systems have been developed to treat intractable human diseases. One approach has been the development of chimeric vector systems combining at least two different vector systems. Based on this concept, chimeric drug delivery systems that combine viral and non-viral features have been developed. Fusigenic non-viral particles have been constructed by conferring viral fusion proteins onto non-viral vectors. HVJ (hemagglutinating virus of Japan; Sendai virus)-liposomes were constructed by the combination of DNA-loaded liposomes with a fusigenic envelope derived from HVJ (hemagglutinating virus of Japan, Sendai virus). Reconstituted HVJ-liposomes were also developed by the insertion of isolated fusion proteins of HVJ into DNA-loaded liposomes. Recently, the technology has been developed to incorporate macromolecules directly into inactivated HVJ particles without liposomes. The resulting HVJ envelope vector introduced plasmid DNA, efficiently and rapidly into both cultured cells in vitro and organs in vivo . Furthermore, proteins, synthetic oligonucleotides and drugs have also been effectively introduced into cells using the HVJ envelope vector. The HVJ envelope vector will be a promising tool for both ex vivo and in vivo gene therapy experiments.
Export Options
About this article
Cite this article as:
Kaneda Yasufumi, New Vector Innovation for Drug Delivery: Development of Fusigenic Non- Viral Particles, Current Drug Targets 2003; 4 (8) . https://dx.doi.org/10.2174/1389450033490740
DOI https://dx.doi.org/10.2174/1389450033490740 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Features in the Treatment of Androgen-Independent Prostate Cancer
Current Pharmaceutical Design Receptor Tyrosine Kinase Kit and Gastrointestinal Stromal Tumours: An Overview
Current Medicinal Chemistry Leucine-zipper and Sterile-α Motif Kinase (ZAK): A Potential Target for Drug Discovery
Current Medicinal Chemistry The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets Erlotinib: A Targeted Anticancer Drug
Current Cancer Therapy Reviews Interplay of Drug-Metabolizing Enzymes and Transporters in Drug Absorption and Disposition
Current Drug Metabolism Treatment and Response to Statins: Gender-related Differences
Current Medicinal Chemistry Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Prognostic and Predictive Value of Epithelial to Mesenchymal Transitionassociated Markers in Oral Squamous Cell Carcinoma
Current Proteomics MT1-MMP Activation of TGF-β Signaling Enables Intercellular Activation of an Epithelial-mesenchymal Transition Program in Cancer
Current Cancer Drug Targets Chemoprevention Gene Therapy (CGT) of Pancreatic Cancer Using Perillyl Alcohol and a Novel Chimeric Serotype Cancer Terminator Virus
Current Molecular Medicine Criteria of Evidence to Move Potential Chemopreventive Agents into Late Phase Clinical Trials
Current Drug Targets Immunotherapy for Myeloproliferative Neoplasms (MPN)
Current Cancer Drug Targets The Hedgehog Knows Many Tricks
Current Drug Targets CYP4 Enzymes As Potential Drug Targets: Focus on Enzyme Multiplicity, Inducers and Inhibitors, and Therapeutic Modulation of 20- Hydroxyeicosatetraenoic Acid (20-HETE) Synthase and Fatty Acid ω- Hydroxylase Activities
Current Topics in Medicinal Chemistry P53 Gene Therapy Sensitizes Resistant Breast Cancer Cells to Doxorubicin Chemotherapy
Drug Delivery Letters Cytokines and Chemokines as Regulators of Angiogenesis in Health and Disease
Current Pharmaceutical Design Chelating Agents for Metal Intoxication
Current Medicinal Chemistry New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
Mini-Reviews in Medicinal Chemistry The Future of Diabetes Management by Healthy Probiotic Microorganisms
Current Diabetes Reviews